CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← NERVGEN PHARMA CORP. (NGEN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

NERVGEN PHARMA CORP. (NGEN)

Pharmaceutical Preparations · market cap $162M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-07-15 (est.)
Phase 3
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
NervGen Pharma Corp. (NGEN) is a 9-employee company with a ~$113M market cap (~79.6M shares at ~$1.42) and a single pipeline asset in our data: NVG-291, in Phase 3 for spinal cord injuries. Our calendar shows an estimated Q-earnings print on 2026-11-12 and an estimated Phase 3 readout for NVG-291 on 2027-07-15 (importance 9/10). Reported cash is $22.1M against a 2025 net loss of $24M.
The catalyst path
  • 2027-07-15 (est.)Phase 3 · NVG-291imp 9/10
Pipeline
AssetPhaseIndication
NVG-291Phase 3Spinal Cord Injuries
Price & technical context
3-month
+11.9%
6-month
-47.3%
12-month
-30.1%
52-wk range
$1.32–$5.97
vs 50-day MA
+8.3%
vs 200-day MA
-29.5%
Realized vol
91.6%
Max drawdown
-77.9%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for NGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.